{"hands_on_practices": [{"introduction": "The design of any engineered system begins with understanding its physical limits. For adeno-associated virus (AAV) vectors, the primary constraint is the finite packaging capacity of the viral capsid, which is typically less than 5,000 base pairs. This exercise [@problem_id:2786877] challenges you to think like a vector engineer, performing a \"genome budgeting\" calculation to determine the available space for a transgene after accounting for all essential regulatory and structural DNA elements. Mastering this simple but critical arithmetic is the first step in constructing a functional and effective gene delivery vehicle.", "problem": "You are designing an Adeno-Associated Virus (AAV) vector to deliver a single Coding Sequence (CDS) to mammalian cells. The AAV packaging constraint is that the total linear genome length inside the capsid, including the two Inverted Terminal Repeats (ITRs), must not exceed a specified limit. The physical principle to use is conservation of length along a contiguous linear sequence: for any arrangement of non-overlapping genetic segments placed end-to-end, the total length equals the sum of individual segment lengths. The central dogma of molecular biology (deoxyribonucleic acid to ribonucleic acid to protein) motivates inclusion of regulatory elements that control transcription and translation, but each element contributes base pairs that consume the finite packaging budget.\n\nAssume the following, and treat all lengths as additive and non-overlapping:\n- The AAV packaging limit is $L_{\\max} = 4700\\,\\text{bp}$.\n- Two ITRs of length $145\\,\\text{bp}$ each are required at the genome ends and count toward the total packaged length.\n- The expression cassette includes: a core promoter of length $900\\,\\text{bp}$; an enhancer array composed of $3$ identical tandem copies of a $200\\,\\text{bp}$ enhancer; a $5^{\\prime}$ Untranslated Region (UTR) of length $120\\,\\text{bp}$; a $3^{\\prime}$ UTR of length $300\\,\\text{bp}$; a polyadenylation (polyA) signal of length $250\\,\\text{bp}$.\n- To insulate the cassette from chromatin position effects, you include two copies (one at each end of the cassette, internal to the ITRs) of the chicken beta-globin hypersensitive site 4 (cHS4) core insulator, each of length $250\\,\\text{bp}$.\n\nStarting from the additivity of lengths along a linear genome and the definition of a packaging limit, first derive a symbolic expression for the maximum allowable CDS length $L_{\\text{CDS,max}}$ in terms of $L_{\\max}$ and the component lengths above. Then substitute the given numerical values to compute the exact remaining CDS capacity. Express your final answer as an exact integer in base pairs (bp). Do not round.", "solution": "The problem as stated is scientifically grounded, well-posed, objective, and contains sufficient information for a unique solution. It is based on the fundamental and valid principle of additive lengths of components in a linear biopolymer and uses realistic parameters for Adeno-Associated Virus (AAV) vector design. Therefore, the problem is valid, and we shall proceed with the derivation and calculation.\n\nThe central constraint of the problem is the AAV packaging limit. The total length of the linear single-stranded DNA genome to be packaged, $L_{\\text{total}}$, must not exceed the maximum capacity of the viral capsid, $L_{\\max}$. This is expressed as an inequality:\n$$L_{\\text{total}} \\leq L_{\\max}$$\n\nThe problem states that the total length is the sum of the lengths of all non-overlapping genetic segments. The components of the vector genome are:\n1.  Two Inverted Terminal Repeats (ITRs), each of length $L_{\\text{ITR}}$. The total length is $2 \\cdot L_{\\text{ITR}}$.\n2.  Two cHS$4$ core insulators, each of length $L_{\\text{insulator}}$. The total length is $2 \\cdot L_{\\text{insulator}}$.\n3.  A core promoter of length $L_{\\text{promoter}}$.\n4.  An enhancer array, which consists of $N_{\\text{enh}} = 3$ identical copies of an enhancer element of length $L_{\\text{enh,unit}}$. The total length of the array is $L_{\\text{enhancer}} = N_{\\text{enh}} \\cdot L_{\\text{enh,unit}}$.\n5.  A $5^{\\prime}$ Untranslated Region (UTR) of length $L_{5'\\text{UTR}}$.\n6.  A $3^{\\prime}$ Untranslated Region (UTR) of length $L_{3'\\text{UTR}}$.\n7.  A polyadenylation signal of length $L_{\\text{polyA}}$.\n8.  The Coding Sequence (CDS) of length $L_{\\text{CDS}}$.\n\nThe total length is the sum of these components:\n$$L_{\\text{total}} = 2 \\cdot L_{\\text{ITR}} + 2 \\cdot L_{\\text{insulator}} + L_{\\text{promoter}} + L_{\\text{enhancer}} + L_{5'\\text{UTR}} + L_{3'\\text{UTR}} + L_{\\text{polyA}} + L_{\\text{CDS}}$$\n\nTo find the maximum allowable CDS length, denoted $L_{\\text{CDS,max}}$, we set the total length equal to the packaging limit $L_{\\max}$:\n$$L_{\\max} = 2 \\cdot L_{\\text{ITR}} + 2 \\cdot L_{\\text{insulator}} + L_{\\text{promoter}} + L_{\\text{enhancer}} + L_{5'\\text{UTR}} + L_{3'\\text{UTR}} + L_{\\text{polyA}} + L_{\\text{CDS,max}}$$\n\nThe first task is to derive a symbolic expression for $L_{\\text{CDS,max}}$. We achieve this by isolating the term $L_{\\text{CDS,max}}$:\n$$L_{\\text{CDS,max}} = L_{\\max} - (2 \\cdot L_{\\text{ITR}} + 2 \\cdot L_{\\text{insulator}} + L_{\\text{promoter}} + L_{\\text{enhancer}} + L_{5'\\text{UTR}} + L_{3'\\text{UTR}} + L_{\\text{polyA}})$$\n\nThis equation represents the symbolic expression for the maximum CDS length. The length available for the CDS is the total packaging capacity minus the summed lengths of all other required genetic elements.\n\nThe second task is to substitute the given numerical values to compute the exact remaining capacity for the CDS. The provided values are:\n- $L_{\\max} = 4700\\,\\text{bp}$\n- $L_{\\text{ITR}} = 145\\,\\text{bp}$\n- $L_{\\text{insulator}} = 250\\,\\text{bp}$\n- $L_{\\text{promoter}} = 900\\,\\text{bp}$\n- Enhancer array: $N_{\\text{enh}} = 3$ copies of $L_{\\text{enh,unit}} = 200\\,\\text{bp}$. Thus, $L_{\\text{enhancer}} = 3 \\cdot 200\\,\\text{bp} = 600\\,\\text{bp}$.\n- $L_{5'\\text{UTR}} = 120\\,\\text{bp}$\n- $L_{3'\\text{UTR}} = 300\\,\\text{bp}$\n- $L_{\\text{polyA}} = 250\\,\\text{bp}$\n\nLet us calculate the total length of all non-CDS components, which we can denote as $L_{\\text{fixed}}$:\n$$L_{\\text{fixed}} = (2 \\cdot 145) + (2 \\cdot 250) + 900 + (3 \\cdot 200) + 120 + 300 + 250$$\nPerforming the multiplications first:\n$$L_{\\text{fixed}} = 290 + 500 + 900 + 600 + 120 + 300 + 250$$\nNow, we sum these values:\n$$L_{\\text{fixed}} = 790 + 900 + 600 + 120 + 300 + 250$$\n$$L_{\\text{fixed}} = 1690 + 600 + 120 + 300 + 250$$\n$$L_{\\text{fixed}} = 2290 + 120 + 300 + 250$$\n$$L_{\\text{fixed}} = 2410 + 300 + 250$$\n$$L_{\\text{fixed}} = 2710 + 250$$\n$$L_{\\text{fixed}} = 2960\\,\\text{bp}$$\n\nThe total length consumed by the fixed regulatory and structural elements is $2960\\,\\text{bp}$. Finally, we subtract this value from the maximum packaging limit to find the maximum possible length for the CDS:\n$$L_{\\text{CDS,max}} = L_{\\max} - L_{\\text{fixed}}$$\n$$L_{\\text{CDS,max}} = 4700 - 2960$$\n$$L_{\\text{CDS,max}} = 1740\\,\\text{bp}$$\n\nThe maximum allowable length for the Coding Sequence is precisely $1740$ base pairs.", "answer": "$$\\boxed{1740}$$", "id": "2786877"}, {"introduction": "A viral vector's concentration, or titer, can be measured in two fundamentally different ways: by counting all physical genomes or by measuring only the particles that can successfully transduce cells. This problem [@problem_id:2786859] explores this critical distinction between physical and functional titer, a key aspect of vector quality control. By analyzing hypothetical experimental data, you will practice calculating functional titer using a Poisson model and critically evaluating the biophysical reasons why not every viral particle is a functional one, a crucial skill for interpreting experimental outcomes.", "problem": "Adeno-associated virus serotype $2$ (AAV2) vectors carrying a cytomegalovirus (CMV) promoter driving green fluorescent protein (GFP) are produced and purified. Physical titer is measured as genome copies per milliliter using quantitative polymerase chain reaction (qPCR) after deoxyribonuclease (DNase) digestion of unpackaged nucleic acids and capsid lysis. The resulting value is $4.0 \\times 10^{12}$ genome copies per $\\mathrm{mL}$. To estimate functional titer as transducing units per milliliter, a limiting-dilution assay is performed on human embryonic kidney $293$T (HEK293T) cells: serial $10$-fold dilutions of the vector are prepared, and for each dilution $0.1\\,\\mathrm{mL}$ is added per well across many replicate wells. A well is scored positive if any GFP signal is detected after $48\\,\\mathrm{h}$. At a $10^{-6}$ dilution, $62\\%$ of wells are GFP positive. Assume independent infection events that are rare and follow a Poisson process across wells, and that a well is positive if it has at least one successful transduction event.\n\nSelect all statements that are correct about the relationship between the physical and functional titers and plausible sources of discrepancy between them.\n\nA. The functional titer is approximately $1.0 \\times 10^{7}$ transducing units per $\\mathrm{mL}$, implying a genome copy to transducing unit ratio of about $4.0 \\times 10^{5}$. A plausible mechanistic contributor is that many capsids package truncated or otherwise damaged genomes that still contain the qPCR target region (and are therefore counted as genome copies) but fail at later steps of transduction, reducing functional titer.\n\nB. The functional titer is approximately $6.2 \\times 10^{6}$ transducing units per $\\mathrm{mL}$ because $62\\%$ positive wells directly indicates an average of $0.62$ successful transduction events per well at the $10^{-6}$ dilution, so dividing by the effective stock volume per well gives the titer.\n\nC. The discrepancy is best explained by a high fraction of empty capsids that are counted by qPCR as genome copies, which inflates the physical titer relative to the functional titer.\n\nD. Using a cell line engineered to overexpress the appropriate AAV2 receptor and co-receptor would be expected to increase the measured functional titer without changing the physical titer, thereby decreasing the genome copy to transducing unit ratio.\n\nE. Residual producer-plasmid DNA or unpackaged vector genomes that are not completely removed prior to qPCR can be amplified and counted as genome copies per $\\mathrm{mL}$, inflating the physical titer relative to the functional titer even though those nucleic acids cannot transduce cells.", "solution": "The problem statement must first be validated for scientific and logical integrity.\n\n**Step 1: Extract Givens**\n-   Vector: Adeno-associated virus serotype $2$ (AAV2)\n-   Transgene Cassette: Cytomegalovirus (CMV) promoter driving green fluorescent protein (GFP)\n-   Physical Titer Measurement Method: Quantitative polymerase chain reaction (qPCR) after deoxyribonuclease (DNase) digestion.\n-   Physical Titer: $T_p = 4.0 \\times 10^{12}$ genome copies (GC) per $\\mathrm{mL}$.\n-   Functional Titer Assay: Limiting-dilution on human embryonic kidney $293$T (HEK293T) cells.\n-   Assay Conditions: Serial $10$-fold dilutions; $V = 0.1\\,\\mathrm{mL}$ of diluted vector added per well.\n-   Assay Readout: A well is positive for GFP signal after $48\\,\\mathrm{h}$ if it contains at least one successful transduction event.\n-   Assay Data: At a dilution factor $D = 10^{-6}$, the fraction of positive wells is $P_{pos} = 0.62$.\n-   Assumption: Infection events are independent and follow a Poisson process.\n\n**Step 2: Validate Using Extracted Givens**\nThe problem describes a standard workflow for producing and titrating a viral vector, a common task in synthetic biology and virology. The methods described—qPCR for physical titer and a limiting-dilution infectivity assay for functional titer—are standard practice. The use of the Poisson distribution to model the results of the limiting-dilution assay is the correct and accepted statistical framework. The values provided for physical titer and the percentage of positive wells are within realistic and expected ranges for AAV vector production. The problem is self-contained, scientifically grounded, and well-posed. It presents a solvable problem based on established principles.\n\n**Step 3: Verdict and Action**\nThe problem is valid. A rigorous solution can be derived.\n\n**Derivation of Functional Titer**\nThe functional assay relies on the Poisson distribution, which gives the probability $P(k)$ of observing $k$ events in a given interval when the average number of events is $\\lambda$.\n$$P(k) = \\frac{\\lambda^k e^{-\\lambda}}{k!}$$\nA well is scored positive if it experiences one or more transduction events ($k \\ge 1$). It is simpler to calculate the probability of a well being negative, which corresponds to zero transduction events ($k=0$).\n$$P(k=0) = \\frac{\\lambda^0 e^{-\\lambda}}{0!} = e^{-\\lambda}$$\nThe problem states that $62\\%$ of wells are positive, so $P_{pos} = 0.62$. The fraction of negative wells, $P_{neg}$, is therefore:\n$$P_{neg} = 1 - P_{pos} = 1 - 0.62 = 0.38$$\nEquating this to the Poisson probability of zero events:\n$$e^{-\\lambda} = 0.38$$\nSolving for $\\lambda$, the average number of transducing units (TUs) per well:\n$$\\lambda = -\\ln(0.38)$$\nUsing the natural logarithm, $\\lambda \\approx -(-0.96758) \\approx 0.9676$.\n\nThis value of $\\lambda$ represents the average number of transducing units in the volume of diluted vector added to each well. The volume added is $V = 0.1\\,\\mathrm{mL}$, and the dilution factor is $D = 10^{-6}$. The functional titer, $T_f$, in transducing units per milliliter (TU/mL) of the original, undiluted stock is therefore:\n$$T_f = \\frac{\\lambda}{V \\times D} = \\frac{0.9676 \\text{ TU}}{(0.1 \\text{ mL}) \\times 10^{-6}}$$\n$$T_f = \\frac{0.9676}{10^{-7}} \\text{ TU/mL} = 9.676 \\times 10^6 \\text{ TU/mL}$$\nThis can be rounded to $T_f \\approx 9.7 \\times 10^6 \\text{ TU/mL}$, or approximately $1.0 \\times 10^7 \\text{ TU/mL}$ to one significant figure for comparison.\n\nThe ratio of physical particles (genome copies, GC) to functional particles (transducing units, TU) is:\n$$\\text{Ratio} = \\frac{T_p}{T_f} = \\frac{4.0 \\times 10^{12} \\text{ GC/mL}}{9.676 \\times 10^6 \\text{ TU/mL}} \\approx 4.13 \\times 10^5 \\text{ GC/TU}$$\n\n**Option-by-Option Analysis**\n\n**A. The functional titer is approximately $1.0 \\times 10^{7}$ transducing units per $\\mathrm{mL}$, implying a genome copy to transducing unit ratio of about $4.0 \\times 10^{5}$. A plausible mechanistic contributor is that many capsids package truncated or otherwise damaged genomes that still contain the qPCR target region (and are therefore counted as genome copies) but fail at later steps of transduction, reducing functional titer.**\n\nMy calculation yields a functional titer of $T_f \\approx 9.7 \\times 10^6 \\text{ TU/mL}$, which is indeed approximately $1.0 \\times 10^7 \\text{ TU/mL}$.\nUsing this rounded titer, the ratio is $\\frac{4.0 \\times 10^{12}}{1.0 \\times 10^7} = 4.0 \\times 10^5$. My more precise calculation gave $4.13 \\times 10^5$, which is consistent. The numerical part of the statement is correct.\nThe mechanistic explanation is also correct. Defective interfering particles and truncated genomes are a known byproduct of AAV production. If the region targeted by the qPCR primers and probe is intact on these defective genomes, they will be counted in the physical titer. However, because the full transgene cassette required for protein expression is damaged, these particles are non-functional, thus contributing to a high physical-to-functional particle ratio.\n**Verdict: Correct**\n\n**B. The functional titer is approximately $6.2 \\times 10^{6}$ transducing units per $\\mathrm{mL}$ because $62\\%$ positive wells directly indicates an average of $0.62$ successful transduction events per well at the $10^{-6}$ dilution, so dividing by the effective stock volume per well gives the titer.**\n\nThis statement makes a fundamental mathematical error. It incorrectly assumes a linear relationship, $\\lambda = P_{pos}$. The correct relationship based on the Poisson model is $\\lambda = -\\ln(1 - P_{pos})$.\nUsing the flawed logic: \"Titer\" = $\\frac{0.62}{0.1 \\times 10^{-6}} = 6.2 \\times 10^6 \\text{ TU/mL}$.\nThis is a common but incorrect shortcut. The approximation $1 - e^{-\\lambda} \\approx \\lambda$ is valid only for $\\lambda \\ll 1$. Here, $P_{pos} = 0.62$ is not sufficiently small for this approximation to be accurate. The correct calculation gives $\\lambda \\approx 0.97$, a substantially different value. The reasoning is flawed.\n**Verdict: Incorrect**\n\n**C. The discrepancy is best explained by a high fraction of empty capsids that are counted by qPCR as genome copies, which inflates the physical titer relative to the functional titer.**\n\nThis statement is factually incorrect regarding the specified measurement technique. The physical titer is measured by qPCR, which quantifies DNA (genome copies). Empty capsids, by definition, lack a genome. Therefore, they are not detected or counted by qPCR. Empty capsids would inflate a physical titer measurement made by a protein-based method like ELISA (which detects capsid proteins) or by specific analytical instrumentation, but not by qPCR as stated in the problem.\n**Verdict: Incorrect**\n\n**D. Using a cell line engineered to overexpress the appropriate AAV2 receptor and co-receptor would be expected to increase the measured functional titer without changing the physical titer, thereby decreasing the genome copy to transducing unit ratio.**\n\nThe functional titer is a measure of a vector's biological activity on a specific cell system. AAV transduction is initiated by binding to specific cell-surface receptors (e.g., AAVR for AAV2) and co-receptors. Increasing the density of these receptors on the target cells can enhance the efficiency of virus entry, a rate-limiting step in transduction. This would lead to a higher probability of successful transduction per applied particle, resulting in a higher measured functional titer ($T_f$). The physical titer ($T_p$) is an intrinsic property of the vector stock itself (the concentration of genomes) and is measured independently of any cell line. Therefore, $T_p$ would remain unchanged. As $T_f$ increases and $T_p$ stays constant, the ratio $T_p/T_f$ must decrease. This statement is scientifically sound.\n**Verdict: Correct**\n\n**E. Residual producer-plasmid DNA or unpackaged vector genomes that are not completely removed prior to qPCR can be amplified and counted as genome copies per $\\mathrm{mL}$, inflating the physical titer relative to the functional titer even though those nucleic acids cannot transduce cells.**\n\nThe problem specifies that the sample is treated with DNase to digest unpackaged nucleic acids prior to capsid lysis and qPCR. The purpose of this step is to ensure that only encapsidated genomes are measured. However, no biochemical reaction is perfectly efficient. It is plausible and common for DNase digestion to be incomplete, leaving residual contaminating plasmid DNA or free vector genomes. This contaminating DNA would be released upon addition of lysis buffer (even if it was never in a capsid) and subsequently amplified by qPCR, leading to an artificially high physical titer. Such free DNA cannot transduce cells in the manner of a viral vector and is thus non-functional. This is a well-known and plausible source of error that inflates the physical titer relative to the true functional titer.\n**Verdict: Correct**", "answer": "$$\\boxed{ADE}$$", "id": "2786859"}, {"introduction": "Beyond efficacy, safety is the most important consideration in developing viral vectors for therapeutic use. The potential for a replication-incompetent vector to become a replication-competent recombinant (RCR) through homologous recombination poses a significant risk. In this exercise [@problem_id:2786878], you will construct a first-principles risk model to quantify the probability of such an event, based on factors like recombination rate and the length of sequence homology. This quantitative approach, including the use of elasticity analysis to identify the most effective mitigation strategies, represents a sophisticated skill required for advanced vector development and regulatory science.", "problem": "A production cell line is used to manufacture a viral gene-delivery vector that is intentionally replication-incompetent. A replication-competent recombinant (RCR) can emerge if two co-packaged genetic elements that share a contiguous homologous region undergo at least one homologous crossover within that region while simultaneously co-localizing in the same subcellular compartment. Let the following quantities be defined for a single cell during the production window:\n- $r$: the per-base-pair initiation rate of homologous crossover during a co-localized encounter (units: event per base pair per co-localized encounter).\n- $L$: the length of the contiguous homologous region between the two genetic elements (units: base pairs).\n- $p_c$: the probability that the two genetic elements co-localize with sufficient spatial and temporal overlap to present the entire homologous region to the homologous recombination machinery in that cell (dimensionless).\n\nUse the following foundational assumptions to construct a minimal risk model grounded in first principles:\n1. Along the homologous tract of length $L$, potential crossover initiations occur as a spatial Poisson process with constant rate $r$ per base pair per co-localized encounter, independent across positions in the tract.\n2. A single successful homologous crossover anywhere within the tract is sufficient to restore replication competence, conditional on co-localization.\n3. Co-localization and crossover are independent events in the probabilistic sense over the production window for a given cell.\n\n(a) Using only the assumptions above and basic probability theory for Poisson processes, derive an expression $P_{\\mathrm{RCR}}(r,L,p_c)$ for the per-cell probability that an RCR arises in the production window as a function of $r$, $L$, and $p_c$.\n\n(b) For local, first-order mitigation analysis, define the elasticity of the risk with respect to a parameter $x \\in \\{r,L,p_c\\}$ by\n$$\nE_x \\equiv \\frac{d \\ln P_{\\mathrm{RCR}}}{d \\ln x} = \\frac{x}{P_{\\mathrm{RCR}}}\\,\\frac{\\partial P_{\\mathrm{RCR}}}{\\partial x}.\n$$\nEvaluate the ordered triple $\\big(E_r,E_L,E_{p_c}\\big)$ at the baseline values $r_0 = 2.0 \\times 10^{-7}$ (per base pair per co-localized encounter), $L_0 = 800$ (base pairs), and $p_{c,0} = 0.10$ (dimensionless). Round each component of the triple to four significant figures.\n\n(c) Based on the elasticities from part (b), identify which single-parameter fractional reduction yields the largest first-order fractional reduction in $P_{\\mathrm{RCR}}$ at the baseline. Provide your reasoning in the derivation but report only the ordered triple $\\big(E_r,E_L,E_{p_c}\\big)$ as your final answer.\n\nProvide your final answer as a row matrix in the order $\\big(E_r,E_L,E_{p_c}\\big)$. No units are to be included in the final answer.", "solution": "We begin from the stated assumptions and basic properties of the Poisson process. Assumption 1 implies that, conditional on co-localization in a given cell, crossover initiations along the homologous tract of length $L$ follow a Poisson process with constant rate (hazard) $r$ per base pair. For a tract of length $L$, the expected number of crossover initiations is therefore\n$$\n\\lambda = r L.\n$$\nFor a Poisson count with mean $\\lambda$, the probability of at least one event is\n$$\n\\Pr(\\text{at least one crossover} \\mid \\text{co-localized}) = 1 - \\exp(-\\lambda) = 1 - \\exp(- r L).\n$$\nAssumption 2 states that a single such crossover suffices to produce an RCR, conditional on co-localization. Assumption 3 states that co-localization occurs with probability $p_c$ and is independent of the crossover process. Therefore, by the law of total probability, the per-cell probability that an RCR arises during the production window is\n$$\nP_{\\mathrm{RCR}}(r,L,p_c) = p_c \\,\\Pr(\\text{at least one crossover} \\mid \\text{co-localized}) = p_c \\big(1 - \\exp(- r L)\\big).\n$$\n\nFor the elasticity analysis, we use the definition\n$$\nE_x \\equiv \\frac{d \\ln P_{\\mathrm{RCR}}}{d \\ln x} = \\frac{x}{P_{\\mathrm{RCR}}}\\,\\frac{\\partial P_{\\mathrm{RCR}}}{\\partial x}.\n$$\nWe compute the partial derivatives of $P_{\\mathrm{RCR}}(r,L,p_c) = p_c \\big(1 - \\exp(- r L)\\big)$ with respect to each parameter.\n\n- With respect to $r$:\n$$\n\\frac{\\partial P_{\\mathrm{RCR}}}{\\partial r} = p_c \\,\\frac{d}{dr}\\big(1 - \\exp(- r L)\\big) = p_c \\, L \\exp(- r L).\n$$\nHence\n$$\nE_r = \\frac{r}{p_c \\big(1 - \\exp(- r L)\\big)} \\, p_c \\, L \\exp(- r L) = \\frac{r L \\exp(- r L)}{1 - \\exp(- r L)}.\n$$\n\n- With respect to $L$:\n$$\n\\frac{\\partial P_{\\mathrm{RCR}}}{\\partial L} = p_c \\,\\frac{d}{dL}\\big(1 - \\exp(- r L)\\big) = p_c \\, r \\exp(- r L),\n$$\nso\n$$\nE_L = \\frac{L}{p_c \\big(1 - \\exp(- r L)\\big)} \\, p_c \\, r \\exp(- r L) = \\frac{r L \\exp(- r L)}{1 - \\exp(- r L)}.\n$$\nThus $E_L = E_r$ by symmetry in $r$ and $L$ through the product $rL$.\n\n- With respect to $p_c$:\n$$\n\\frac{\\partial P_{\\mathrm{RCR}}}{\\partial p_c} = 1 - \\exp(- r L),\n$$\nso\n$$\nE_{p_c} = \\frac{p_c}{p_c \\big(1 - \\exp(- r L)\\big)} \\,\\big(1 - \\exp(- r L)\\big) = 1.\n$$\n\nTherefore, the elasticities in closed form are\n$$\nE_r = E_L = \\frac{r L \\exp(- r L)}{1 - \\exp(- r L)} = \\frac{r L}{\\exp(r L) - 1}, \\quad\\text{and}\\quad E_{p_c} = 1.\n$$\n\nWe now evaluate these at the baseline parameters $r_0 = 2.0 \\times 10^{-7}$, $L_0 = 800$, and $p_{c,0} = 0.10$. Define $z \\equiv r_0 L_0$:\n$$\nz = (2.0 \\times 10^{-7}) \\times 800 = 1.6 \\times 10^{-4}.\n$$\nThen\n$$\nE_r(r_0,L_0,p_{c,0}) = E_L(r_0,L_0,p_{c,0}) = \\frac{z}{\\exp(z) - 1}.\n$$\nUsing the series for small $z$ or direct computation,\n$$\n\\exp(z) - 1 \\approx 0.0001600128,\n$$\nso\n$$\nE_r \\approx \\frac{0.00016}{0.0001600128} \\approx 0.99992,\\quad E_L \\approx 0.99992,\n$$\nand\n$$\nE_{p_c} = 1.\n$$\nRounding each to four significant figures yields\n$$\nE_r = 0.9999,\\quad E_L = 0.9999,\\quad E_{p_c} = 1.000.\n$$\n\nInterpretation for mitigation prioritization: at the given baseline, all three elasticities are approximately unity, meaning that a small fractional reduction in any of $r$, $L$, or $p_c$ produces nearly the same fractional reduction in $P_{\\mathrm{RCR}}$. However, exactly, $E_{p_c} = 1$ while $E_r = E_L = \\frac{z}{\\exp(z) - 1} < 1$ for any $z > 0$, so a fractional reduction in $p_c$ yields the largest first-order fractional reduction in $P_{\\mathrm{RCR}}$, with reductions in $r$ or $L$ essentially equally effective but marginally less so at this baseline.", "answer": "$$\\boxed{\\begin{pmatrix}0.9999 & 0.9999 & 1.000\\end{pmatrix}}$$", "id": "2786878"}]}